Natera Inc (NTRA) Stock Price, Quote & News

Company Profile

Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples und...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 650 980 9190

Website: www.natera.com

Address:

13011 McCallen Pass, Building A Suite 100, Austin, United States

rottieluvr3 Jun. 21 at 4:49 PM

$NTRA This is one of those stocks that basically follows 1 trend line. Above it is a sell, below it is a buy. It’s currently below so I’m a buyer.

0 · Reply

Monkey_Banana_Genius Jun. 18 at 6:42 PM

$NTRA YO WELCOME. LONG

0 · Reply

Monkey_Banana_Genius Jun. 18 at 6:39 PM

$ASTS $GH $NTRA $RKLB $TTWO ❤️🐒🍌🧠. LONG

1 · Reply

Mustardill Jun. 18 at 3:59 PM

$EXAS starting to feel bad for how much this stock lags compared to $GH and $NTRA. Can’t say I didn’t tell you.

2 · Reply

WAJeff Jun. 18 at 2:53 PM

$NTRA 5/9 $148.77s sold at $169.98

2 · Reply

roblake29 Jun. 17 at 10:58 PM

$NTRA An update on my thesis: https://seekingalpha.com/article/4795412-natera-growth-likely-to-moderate-despite-signatera-test-medicare-coverage

1 · Reply

Mustardill Jun. 16 at 2:27 PM

$EXAS very impressive how often this goes down. Buy $GH or $NTRA instead!

1 · Reply

Monkey_Banana_Genius Jun. 14 at 10:22 PM

$ASTS $GH $NTRA $RKLB $TTWO so far so good

1 · Reply

Vandenberg23 Jun. 12 at 4:30 PM

$NTRA this company is tops in the sector

1 · Reply

Mustardill Jun. 12 at 2:20 PM

$EXAS this stock is ass 😂😂😂 time to sell and buy $GH or $NTRA instead

1 · Reply

Natera Announces Medicare Coverage for Signatera™ Genome

Jun 2, 2025, 4:05 PM EDT - 22 days ago

SignateraTM Genome Clinical Performance Highlighted at ASCO 2025

May 22, 2025, 5:08 PM EDT - 4 weeks ago

Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting

May 16, 2025, 8:41 AM EDT - 5 weeks ago

Natera: The Clues In Q1 Earnings

May 8, 2025, 8:58 PM EDT - 6 weeks ago

Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 6 weeks ago

Natera Reports First Quarter 2025 Financial Results

May 8, 2025, 10:30 AM EDT - 6 weeks ago

Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress

May 7, 2025, 7:00 AM EDT - 6 weeks ago

Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows

May 5, 2025, 7:00 AM EDT - 7 weeks ago

Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera

May 1, 2025, 7:00 AM EDT - 7 weeks ago

Natera to Report its First Quarter Results on May 8, 2025

Apr 29, 2025, 4:05 PM EDT - 2 months ago

Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction

Apr 29, 2025, 11:45 AM EDT - 2 months ago

Baron Health Care Fund Q1 2025 Top Net Purchases And Sales

ACLX ISRG MASI MCK PEN TMO UNH

Apr 24, 2025, 7:00 AM EDT - 2 months ago

Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test

Apr 22, 2025, 4:05 PM EDT - 2 months ago

Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting

Mar 25, 2025, 7:00 AM EDT - 3 months ago

DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting

Mar 17, 2025, 11:52 AM EDT - 3 months ago

Natera: Growth Looks Unstoppable, Positive EPS Just A Matter Of Time

Mar 10, 2025, 8:00 AM EDT - 3 months ago

Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer

Mar 4, 2025, 7:00 AM EST - 4 months ago

Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD

Feb 28, 2025, 12:23 AM EST - 4 months ago

Natera, Inc. (NTRA) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 4 months ago

Natera Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 25, 2025, 6:00 AM EST - 4 months ago

Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer

Feb 18, 2025, 9:00 AM EST - 4 months ago

Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025

Feb 10, 2025, 7:00 AM EST - 4 months ago

NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma

Feb 3, 2025, 7:00 AM EST - 5 months ago

Natera Announces National Commercial Coverage for its Fetal RhD NIPT

Jan 25, 2025, 10:05 AM EST - 5 months ago

Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer

Jan 21, 2025, 6:05 PM EST - 5 months ago

Natera to Present New Data at the 2025 ASCO GI Symposium

Jan 17, 2025, 9:00 AM EST - 5 months ago

Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year

Jan 15, 2025, 7:00 AM EST - 5 months ago

Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection

Jan 12, 2025, 7:20 PM EST - 5 months ago

Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024

Jan 7, 2025, 9:00 AM EST - 6 months ago

Natera to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Jan 3, 2025, 2:00 PM EST - 6 months ago

Undercovered Dozen: Natera, Lloyds Banking Group, Eaton, Primoris Services +

LYG PRIM

Dec 31, 2024, 5:50 AM EST - 6 months ago

Natera: Poised For A Great Future But I'd Wait For A Pullback

Dec 20, 2024, 2:27 PM EST - 6 months ago

Stanley Druckenmiller's Top Holding Has Outperformed Its Sector By 252%

Dec 17, 2024, 8:00 AM EST - 6 months ago

Court Grants Natera's Request to Include Additional Patent in its Lawsuit Against NeoGenomics

Dec 12, 2024, 8:00 AM EST - 6 months ago

Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer

Dec 9, 2024, 8:00 AM EST - 7 months ago

Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment

Dec 2, 2024, 8:00 AM EST - 7 months ago

Clinical Validation Study on Natera's Fetal RhD NIPT Published in Obstetrics & Gynecology

Nov 27, 2024, 9:00 AM EST - 7 months ago

Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients

Nov 25, 2024, 7:57 PM EST - 7 months ago

Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium

Nov 25, 2024, 5:09 PM EST - 7 months ago

Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™

Nov 25, 2024, 3:51 PM EST - 7 months ago

Natera Issues Statement on Guardant Health Litigation

Nov 25, 2024, 9:00 AM EST - 7 months ago

Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the Year

Nov 21, 2024, 5:31 PM EST - 7 months ago

Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM

Nov 12, 2024, 11:51 PM EST - 7 months ago

Natera, Inc. (NTRA) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 8 months ago

Natera Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 7:00 AM EST - 8 months ago

Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer

Nov 8, 2024, 9:00 AM EST - 8 months ago

Natera to Participate in Upcoming Investor Conferences

Nov 1, 2024, 9:00 AM EDT - 8 months ago

Natera to Report its Third Quarter 2024 Results on November 12, 2024

Oct 31, 2024, 6:00 AM EDT - 8 months ago

Cigna Turns $739 Million Profit Despite $1 Billion Loss On VillageMD

Oct 22, 2024, 9:00 AM EDT - 8 months ago

Natera to Present New Renasight Data at ASN Kidney Week 2024

rottieluvr3 Jun. 21 at 4:49 PM

$NTRA This is one of those stocks that basically follows 1 trend line. Above it is a sell, below it is a buy. It’s currently below so I’m a buyer.

0 · Reply

Monkey_Banana_Genius Jun. 18 at 6:42 PM

$NTRA YO WELCOME. LONG

0 · Reply

Monkey_Banana_Genius Jun. 18 at 6:39 PM

$ASTS $GH $NTRA $RKLB $TTWO ❤️🐒🍌🧠. LONG

1 · Reply

Mustardill Jun. 18 at 3:59 PM

$EXAS starting to feel bad for how much this stock lags compared to $GH and $NTRA. Can’t say I didn’t tell you.

2 · Reply

WAJeff Jun. 18 at 2:53 PM

$NTRA 5/9 $148.77s sold at $169.98

2 · Reply

roblake29 Jun. 17 at 10:58 PM

$NTRA An update on my thesis: https://seekingalpha.com/article/4795412-natera-growth-likely-to-moderate-despite-signatera-test-medicare-coverage

1 · Reply

Mustardill Jun. 16 at 2:27 PM

$EXAS very impressive how often this goes down. Buy $GH or $NTRA instead!

1 · Reply

Monkey_Banana_Genius Jun. 14 at 10:22 PM

$ASTS $GH $NTRA $RKLB $TTWO so far so good

1 · Reply

Vandenberg23 Jun. 12 at 4:30 PM

$NTRA this company is tops in the sector

1 · Reply

Mustardill Jun. 12 at 2:20 PM

$EXAS this stock is ass 😂😂😂 time to sell and buy $GH or $NTRA instead

1 · Reply

RockyMontana Jun. 12 at 12:49 AM

$PSNL $TEM $GRAL $GH $NTRA

0 · Reply

TripleWitch Jun. 9 at 5:29 PM

$PSNL upward trend on the daily chart is approaching a key level. Feels like reimbursement news is coming soon after $NTRA received approval. Expecting a move higher💥

0 · Reply

Mustardill Jun. 5 at 3:21 PM

$EXAS does this thing ever go up? Competitors stealing lots of market share. Time to sell. Buy $GH or $NTRA instead. Just look at the charts!

0 · Reply

Monkey_Banana_Genius Jun. 4 at 5:57 PM

$ASTS $GH $NTRA LONG all and crushing even while on vacay. There is no other. Only ☝️ 🐒🍌🧠.

2 · Reply

OptionRunners Jun. 4 at 5:44 PM

$NTRA Trader sold (to close) the July 18th $145 calls 800 times for $25.45 and bough (to open) the September 19th $175 calls 1,200 times for $13.75. The trader is rolling/adjusting the calls out and up for a $386K credit

0 · Reply

Doozio Jun. 4 at 5:40 PM

$NTRA spread it will spread it must 🐒🍌🧠⏰♾️

0 · Reply

WAJeff Jun. 4 at 3:46 PM

$NTRA On the move

0 · Reply

DonCorleone77 Jun. 4 at 11:41 AM

$NTRA Natera announces Medicare coverage for Signatera MRD assay Natera announced that its genome-based Signatera MRD assay is now covered by Medicare under LCD L38779. This coverage decision applies to Medicare beneficiaries with colorectal cancer, breast cancer, bladder cancer, ovarian cancer, lung cancer, and pan-cancer immunotherapy monitoring, mirroring the pre-existing coverage for Signatera.

0 · Reply

Doozio Jun. 2 at 10:35 PM

$NTRA 🐒🍌🧠⏰♾️

1 · Reply

Doozio Jun. 1 at 2:42 PM

$NTRA chop chop huckleberries out of the tightness wen all da SKWD jabroni 🐑 been SPOT during 🐒🍌🧠⏰♾️

0 · Reply

ChessGM Jun. 1 at 12:32 PM

$NTRA https://chessgmstocks.substack.com/p/deep-dive-on-stanley-druckenmillers?r=2hmnhp&utm_campaign=post&utm_medium=web&triedRedirect=true .

0 · Reply

WAJeff May. 29 at 1:36 PM

$NTRA 5/9 148.34s sold at 165.50 20 days later = 11.5% gain

0 · Reply

Market Cap	23.47B
Revenue (ttm)	1.70B
Net Income (ttm)	-190.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-11.22%
Debt to Equity Ratio	0.06

Volume	935,400
Avg Vol	1,223,550
Day's Range	N/A - N/A
Shares Out	136.55M
Stochastic %K	74%
Beta	1.74
Analysts	Strong Sell
Price Target	$200.42